Oric Pharmaceuticals announced that its prostate cancer drug rinzimetostat is only as effective as competitors, not the best in its class as expected. This announcement led to a 41% drop in Oric's stock price. Following this, Pomerantz LLP launched an investigation into potential securities fraud or unlawful practices by Oric and its officers. Investors affected by the stock drop are encouraged to contact the law firm for possible class action participation.
Senator Elizabeth Warren condemned President Donald Trump for making millions in Nvidia stock trades during key AI chip policy developments involving China. Trump's financial disclosures revealed over 3,700 transactions worth hundreds of millions in ...
Charter Communications' stock has dropped 35%, yet the company maintains confidence in its free cash flow and margin resilience despite competitive pressures and debt challenges. Its near-term debt maturities are manageable, with projections showing ...
Western Midstream Partners (WES) reported strong Q1 results with a record $683.1 million adjusted EBITDA, a 15% year-over-year increase, and a 2.2% rise in distributions. The company announced a $1.6 billion acquisition of Brazos Delaware, expanding ...
Ethereum's price dropped to $2,250 as traders engaged in profit-taking at levels not seen in three weeks. This pullback suggests some investors are locking in gains after recent price increases. The decline could signal short-term caution in the mark...
Intercontinental Exchange (ICE) and Chicago Mercantile Exchange (CME) are pressing U.S. regulators to scrutinize Hyperliquid, a decentralized exchange that allows users to create new energy trading markets by staking 500,000 HYPE tokens, worth about ...
